ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Fracture risks in patients with arginine vasopressin deficiency: a nationwide matched cohort study.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Arginine vasopressin deficiency (AVP-D) might increase fracture risk. This nationwide cohort study found a significantly increased hip fracture risk in female AVP-D patients ≥ 50 years, but not in males. These findings highlight sex-specific vulnerability, urging focused fracture prevention in female AVP-D patients. PURPOSE: Arginine vasopressin deficiency (AVP-D) is associated with various complications and increased mortality. However, its association with long-term fracture risk remains unclear. We aimed to assess fracture risks in patients aged 50 years or older with AVP-D.
methodsWe used data from the Korea National Health Insurance Service database (2003-2020). A total of 3,497 patients aged ≥ 50 years diagnosed with AVP-D (2,111 men and 1,386 women) were included, along with 1:1 matched controls, based on age, sex, index year, and key comorbidities, including diabetes mellitus, hypertension, cardiovascular disease, and cerebrovascular disease. Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for the risk of major osteoporotic fractures (MOFs), vertebral fractures (VFs), non-vertebral fractures (non-VFs), and hip fractures (HFs).
resultsAfter adjusting for confounding factors, including income status, steroid use, and prior fracture history, the risk for MOFs, VFs, non-VFs, and HFs in male patients with AVP-D were comparable to those in controls. In women with AVP-D, the risk of MOFs, VFs, or non-VFs was not different from controls, but the risk of HFs was significantly higher (HR 1.83; 95% CI, 1.06-3.17). Age, female, previous history of fracture, and steroid use contributed to high risk for fracture in patients with AVP-D.
conclusionCompared with controls, only female patients with AVP-D demonstrated a significantly increased risk of HFs. These findings highlight the need for long-term follow-up, targeted screening, and proactive management of HF risk in female patients with AVP-D.
Indexed as
Identifiers
41603925What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.